Business & Finance

Nabi reports Q3 2006 revenue of $26.4 million, down from $30.5 million a year ago

Published in Drug Law Weekly, November 21st, 2006

Nabi Biopharmaceuticals (NABI) announced that revenues, including revenues from PhosLo (calcium acetate), which will be reported as discontinued operations beginning in the third quarter of 2006, were $26.4 million for the third quarter of 2006 compared to $30.5 million in the third quarter of 2005.

Nabi-HB (hepatitis B immune globulin (human)) revenues were lower as the company continues to negotiate the terms of a supply contract with one of its product distributors. Cash, cash equivalents and marketable securities were $64.9 million at the end of the third quarter of 2006. During the third quarter of 2006, cash used in operating activities was $4.3 million compared...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2006-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry